A recent study demonstrated that SHARP1 is highly expressed in renal cell carcinoma cells and its overexpression accelerated tumor progression in xenograft models49, whereas in triple negative breast cancers, SHARP1 mediates the anti-metastatic function of p63 by degrading HIF-1α, and its overexpression is associated with a favorable prognosis50. Here, BHLHE41 is linked to triple-negative breast carcinoma.